vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Kodiak Gas Services, Inc. (KGS). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $332.9M, roughly 1.5× Kodiak Gas Services, Inc.). Kodiak Gas Services, Inc. runs the higher net margin — 7.4% vs -10.1%, a 17.5% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 7.5%). Kodiak Gas Services, Inc. produced more free cash flow last quarter ($142.0M vs $-69.0M). Over the past eight quarters, Kodiak Gas Services, Inc.'s revenue compounded faster (24.3% CAGR vs 18.6%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Kodiak Gas Services, Inc. is a leading natural gas compression services provider operating primarily across North America. It serves upstream and midstream energy sector clients, offering custom compression equipment, regular maintenance, and operational support to optimize natural gas gathering, processing, and transportation workflows for onshore oil and gas production operations.

CLOV vs KGS — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.5× larger
CLOV
$487.7M
$332.9M
KGS
Growing faster (revenue YoY)
CLOV
CLOV
+37.2% gap
CLOV
44.7%
7.5%
KGS
Higher net margin
KGS
KGS
17.5% more per $
KGS
7.4%
-10.1%
CLOV
More free cash flow
KGS
KGS
$211.0M more FCF
KGS
$142.0M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
KGS
KGS
Annualised
KGS
24.3%
18.6%
CLOV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLOV
CLOV
KGS
KGS
Revenue
$487.7M
$332.9M
Net Profit
$-49.3M
$24.6M
Gross Margin
Operating Margin
-10.1%
26.1%
Net Margin
-10.1%
7.4%
Revenue YoY
44.7%
7.5%
Net Profit YoY
-123.2%
29.0%
EPS (diluted)
$0.30

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
KGS
KGS
Q4 25
$487.7M
$332.9M
Q3 25
$496.6M
$322.7M
Q2 25
$477.6M
$322.8M
Q1 25
$462.3M
$329.6M
Q4 24
$337.0M
$309.5M
Q3 24
$331.0M
$324.6M
Q2 24
$356.3M
$309.7M
Q1 24
$346.9M
$215.5M
Net Profit
CLOV
CLOV
KGS
KGS
Q4 25
$-49.3M
$24.6M
Q3 25
$-24.4M
$-14.0M
Q2 25
$-10.6M
$39.5M
Q1 25
$-1.3M
$30.4M
Q4 24
$-22.1M
$19.1M
Q3 24
$-9.2M
$-5.6M
Q2 24
$7.4M
$6.2M
Q1 24
$-19.2M
$30.2M
Gross Margin
CLOV
CLOV
KGS
KGS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
24.5%
37.5%
Q2 24
30.3%
36.5%
Q1 24
23.6%
39.4%
Operating Margin
CLOV
CLOV
KGS
KGS
Q4 25
-10.1%
26.1%
Q3 25
-4.9%
19.9%
Q2 25
-2.2%
30.9%
Q1 25
-0.3%
27.1%
Q4 24
-6.4%
22.3%
Q3 24
-2.7%
20.4%
Q2 24
2.0%
17.5%
Q1 24
-6.5%
27.9%
Net Margin
CLOV
CLOV
KGS
KGS
Q4 25
-10.1%
7.4%
Q3 25
-4.9%
-4.3%
Q2 25
-2.2%
12.2%
Q1 25
-0.3%
9.2%
Q4 24
-6.6%
6.2%
Q3 24
-2.8%
-1.7%
Q2 24
2.1%
2.0%
Q1 24
-5.5%
14.0%
EPS (diluted)
CLOV
CLOV
KGS
KGS
Q4 25
$0.30
Q3 25
$-0.17
Q2 25
$0.43
Q1 25
$0.33
Q4 24
$0.18
Q3 24
$-0.07
Q2 24
$0.06
Q1 24
$0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
KGS
KGS
Cash + ST InvestmentsLiquidity on hand
$78.3M
$3.2M
Total DebtLower is stronger
$2.6B
Stockholders' EquityBook value
$308.7M
$1.2B
Total Assets
$541.0M
$4.3B
Debt / EquityLower = less leverage
2.12×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
KGS
KGS
Q4 25
$78.3M
$3.2M
Q3 25
$724.0K
Q2 25
$5.4M
Q1 25
$1.9M
Q4 24
$194.5M
$4.8M
Q3 24
$288.0M
$7.4M
Q2 24
$254.8M
$3.9M
Q1 24
$208.3M
$9.3M
Total Debt
CLOV
CLOV
KGS
KGS
Q4 25
$2.6B
Q3 25
$2.6B
Q2 25
$2.5B
Q1 25
$2.6B
Q4 24
$2.6B
Q3 24
$2.6B
Q2 24
$2.5B
Q1 24
Stockholders' Equity
CLOV
CLOV
KGS
KGS
Q4 25
$308.7M
$1.2B
Q3 25
$340.9M
$1.3B
Q2 25
$344.2M
$1.3B
Q1 25
$336.1M
$1.4B
Q4 24
$341.1M
$1.4B
Q3 24
$342.2M
$1.4B
Q2 24
$324.9M
$1.5B
Q1 24
$292.5M
$1.1B
Total Assets
CLOV
CLOV
KGS
KGS
Q4 25
$541.0M
$4.3B
Q3 25
$559.7M
$4.4B
Q2 25
$575.0M
$4.4B
Q1 25
$583.7M
$4.4B
Q4 24
$580.7M
$4.4B
Q3 24
$653.0M
$4.5B
Q2 24
$674.2M
$4.4B
Q1 24
$671.8M
$3.3B
Debt / Equity
CLOV
CLOV
KGS
KGS
Q4 25
2.12×
Q3 25
2.08×
Q2 25
1.89×
Q1 25
1.91×
Q4 24
1.88×
Q3 24
1.86×
Q2 24
1.71×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
KGS
KGS
Operating Cash FlowLast quarter
$-66.9M
$194.9M
Free Cash FlowOCF − Capex
$-69.0M
$142.0M
FCF MarginFCF / Revenue
-14.1%
42.7%
Capex IntensityCapex / Revenue
0.4%
15.9%
Cash ConversionOCF / Net Profit
7.91×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$284.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
KGS
KGS
Q4 25
$-66.9M
$194.9M
Q3 25
$12.1M
$113.4M
Q2 25
$5.4M
$177.2M
Q1 25
$-16.3M
$114.3M
Q4 24
$34.8M
$118.5M
Q3 24
$50.0M
$36.9M
Q2 24
$44.8M
$121.1M
Q1 24
$25.9M
$51.5M
Free Cash Flow
CLOV
CLOV
KGS
KGS
Q4 25
$-69.0M
$142.0M
Q3 25
$11.4M
$10.9M
Q2 25
$4.8M
$94.6M
Q1 25
$-16.5M
$36.8M
Q4 24
$33.3M
$45.2M
Q3 24
$49.6M
$-49.7M
Q2 24
$44.4M
$4.0M
Q1 24
$25.5M
$-8.6M
FCF Margin
CLOV
CLOV
KGS
KGS
Q4 25
-14.1%
42.7%
Q3 25
2.3%
3.4%
Q2 25
1.0%
29.3%
Q1 25
-3.6%
11.2%
Q4 24
9.9%
14.6%
Q3 24
15.0%
-15.3%
Q2 24
12.5%
1.3%
Q1 24
7.3%
-4.0%
Capex Intensity
CLOV
CLOV
KGS
KGS
Q4 25
0.4%
15.9%
Q3 25
0.1%
31.7%
Q2 25
0.1%
25.6%
Q1 25
0.0%
23.5%
Q4 24
0.5%
23.7%
Q3 24
0.1%
26.7%
Q2 24
0.1%
37.8%
Q1 24
0.1%
27.9%
Cash Conversion
CLOV
CLOV
KGS
KGS
Q4 25
7.91×
Q3 25
Q2 25
4.49×
Q1 25
3.76×
Q4 24
6.21×
Q3 24
Q2 24
6.04×
19.44×
Q1 24
1.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

KGS
KGS

Other Services$126.8M38%
Other$112.2M34%
Transferred At Point In Time$93.8M28%

Related Comparisons